Novel ATR Inhibitor Shows Promise in Children With Tumors

The novel ataxia telangiectasia–mutated Rad3-related (ATR) inhibitor, ceralasertib, showed some promise in combination with olaparib in pediatric patients with tumors with DNA repair deficiencies.
MDedge News